Table 1. Patient data and characteristics before ECMO.
All | No exchange | System-exchange | p-value | |
Patients (n) | 265 | 182 | 83 | |
Age (years) | 50 (36–60) | 50 (37–61) | 50 (36–60) | 0.844 |
Females (n; %) | 90; 34 | 59; 32 | 31; 37 | 0.518 |
BMI (kg * m-2) | 27.8 (24.7–33.1) | 28.1 (24.8–32.9) | 27.5 (23.9–34.2) | 0.545 |
Ventilation (days) | 1.0 (1.0–6.0) | 1.0 (1.0–5.3) | 2.0 (1.0–6.5) | 0.431 |
SOFA score | 11.0 (8.0–14.3) | 12.0 (8.0–15.0) | 11.0 (8.0–13.0) | 0.067 |
LIS | 3.33 (3.33–3.67) | 3.33 (3.33–3.67) | 3.33 (3.33–3.67) | 0.660 |
ARF (n; %) | 60; 22 | 55; 30 | 5; 6 | ≤0.001 |
NE (µg/kg/min) | 0.26 (0.10–0.51) | 0.27 (0.10–0.51) | 0.22 (0.08–0.53) | 0.425 |
PaO2/FiO2 (mmHg) | 65 (52–85) | 65 (51–84) | 69 (52–86) | 0.554 |
PaCO2 (mmHg) | 64 (51–80) | 63 (50–79) | 64 (54–88) | 0.252 |
apH | 7.24 (7.15–7.34) | 7.23 (7.13–7.33) | 7.24 (7.15–7.35) | 0.453 |
TV (ml) | 470 (396–562) | 477 (399–565) | 455 (358–560) | 0.447 |
TV/kg pred. BW (ml/kg) | 5.6 (4.2–6.7) | 5.6 (4.4–6.7) | 5.3 (3.8–6.7) | 0.413 |
Minute ventilation (l/min) | 10.6 (8.3–12.6) | 11.0 (8.6–12.6) | 10.5 (7.9–12.6) | 0.517 |
PIP (cm H2O) | 35 (30–39) | 35 (30–39) | 35 (30–40) | 0.813 |
PEEP (cm H2O) | 15 (13–18) | 15 (13–18) | 15 (13–18) | 0.505 |
ECMO indication § | 0.001 | |||
1 (n; %) | 150; 57 | 92; 51 | 58; 70 | |
2 (n; %) | 53; 20 | 45; 25 | 8; 10 | |
3 (n; %) | 33; 12 | 28; 15 | 5; 6 | |
4 (n; %) | 29; 11 | 17; 9 | 12; 14 |
Data are presented as median (interquartile range) except for females and acute renal failure. SOFA, Sequential Organ Failure Assessment; LIS, Murray lung injury score; apH, arterial pH value; PaCO2, partial pressure of arterial carbon dioxide; PaO2/FiO2, ratio of partial pressure of arterial oxygen and fraction of inspired oxygen; PIP, peek inspiratory pressure; PEEP, positive end-expiratory pressure; TV, tidal volume; BMI, body mass index; ARF, acute renal failure; NE, Norepinephrine.
ECMO indications: 1, primary lung failure (bacterial, viral, fungal, aspiration pneumonia and H1N1 infection); 2, sepsis with secondary lung failure; 3, trauma with ARDS; 4, other pathologies (eg. pulmonary fibrosis, pulmonary hypertension, pulmonary emboli, extensive bronchiectasis, pulmonary bleeding, tracheal laceration).